65 Hayden Ave.
96 articles about LogicBio Therapeutics
LogicBio Therapeutics Extends Sponsored Research Agreement with Oregon Health & Science University to Explore Translation of Pharmaceutically-Driven Selective Advantage for Future GeneRide™ Candidates
LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced it has entered into an exclusive license with Oregon Health & Science University (“OHSU”) to intellectual property rights owned by OHSU while also extending a sponsored research agreement
LogicBio Reports Third Quarter 2019 Financial Results and Provides Business Updates
LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today reported financial results and provided a corporate update for the third quarter ended September 30, 2019
LogicBio Therapeutics to Present at November Conferences
LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced it will present at the following upcoming healthcare conferences:
LogicBio Therapeutics to Present New Data on Next Generation Capsid Development Program and GeneRide™ Platform Program at the European Society of Gene and Cell Therapy 27th Annual Congress– Panel Presentation on AAV Manufacturing –
LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced upcoming presentations at the European Society of Gene and Cell Therapy (ESGCT) 27th Annual Congress, held in Barcelona, Spain, October 22-25, 2019.
Following last year’s stellar initial public offering in October, where it raised $80.5 million, about $10 million over initial expectations, LogicBio Therapeutics is planning a gene-editing clinical trial in children.
The Nasdaq indicated that there was a record amount of biotech initial public offerings this year, including some individual record-breakers—Moderna, Allogene Therapeutics and Rubius Therapeutics. The total for the year is around $8.2 billion raised, breaking 2014’s record of $6.5 billion.
A summary of IPOs from companies in the biotech and pharma world since Oct. 1, 2018.
A Look Back at October Life Sciences IPOs
10/31/2018October was a busy month as multiple biopharma companies made their debut as publicly traded entities and even more companies filed their intentions to go public with an initial public offering. BioSpace takes a look back at some of the key IPOs of the month.
Chardan Serves as Lead Manager for LogicBio Therapeutics
Chardan announced today that the firm acted as lead manager in the initial public offering of LogicBio Therapeutics, Inc. (NASDAQ: LOGC), raising aggregate gross proceeds of approximately $70.0 million. LogicBio began trading on the NASDAQ Capital Market on October 19, 2018.
LogicBio Therapeutics Appoints Dean Falb, Ph.D., as Chief Scientific Officer
Genome editing company adds drug development expert in pursuit of breakthrough medicines for pediatric patients
LogicBio Therapeutics Launches Development Program in Methylmalonic Acidemia (MMA)
Preclinical data demonstrate potential for LB-001 to address the underlying cause of MMA
There have been a number of leadership changes in biotech companies over the last week. BioSpace has put together a list of new c-suite level hires and position changes.
LogicBio Therapeutics Strengthens Leadership Team with Key Appointments
LogicBio Therapeutics, Inc. announced the appointment of Sandra Poole as chief operating officer, and Paul Herzich as senior director of manufacturing.
LogicBio Therapeutics Announces Expansion of Leadership Team Through Multiple Key Hires
LogicBio Therapeutics today announced the expansion of its leadership team with the appointment of four seasoned industry leaders
LogicBio Announces $50 Million In Financing To Develop Novel Gene Medicines For Pediatric Patients
Arix Bioscience Leads $45 Million Series B Financing Round Into LogicBio